We have an updated report [Version - 2024] available. Kindly sign up to get the sample of the report.
all report title image
  • Published On : Apr 2023
  • Code : CMI2629
  • Pages :170
  • Formats :
      Excel and PDF
  • Industry : Biotechnology

The global antibodies market is estimated to be valued at US$ 224,083.5 million in 2023 and is expected to exhibit a CAGR of 12.9% during the forecast period (2023-2030).

Analysts’ Views on Global Antibodies Market: 

Increasing inorganic strategies such as collaborations by the key market players is expected to drive the global antibodies market over the forecast period. For instance, in March 2022, Sanofi, a pharmaceutical and healthcare company, and Seagen Inc., a biotechnology company, announced a collaboration agreement, to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. The collaboration will utilize Sanofi’s proprietary monoclonal antibody (mAb) technology and Seagen’s proprietary ADC technology

Figure 1. Global Antibodies Market Share (%), By Drug Type, 2023

ANTIBODIES MARKET

To learn more about this report, request a free sample copy

Global Antibodies Market – Driver

Increase in inorganic strategies

Increasing inorganic strategies such as collaboration by the key market players is expected to drive the global antibodies market over the forecast period. For instance, in September 2020, Eli Lilly and Company, a pharmaceutical company and Amgen, an U.S. based multinational biopharmaceutical company, announced a global antibody manufacturing collaboration, to significantly increase the supply capacity available for Lilly's potential COVID-19 therapies.

Figure 2. Global Antibodies Market Value (US$ Million), By Region, 2023

ANTIBODIES MARKET

To learn more about this report, request a free sample copy

Global Antibodies Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global antibodies market over the forecast period.   

Global Antibodies Market – Impact of Coronavirus (COVID-19) Pandemic

Since the COVID-19 virus outbreak in December 2019, the disease spread to over 100 countries across the globe, and the World Health Organization declared it a public health emergency on January 30, 2020.

COVID-19 affected the economy in three main ways: by directly affecting the production and demand of drugs, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, the U.A.E., Egypt, and others are facing problems with the transportation of drugs from one place to another.

The COVID-19 affected the antibodies market positively as demand for the antibodies increased. For instance, in January 2022, a data was published by the Biomed Central, an open access publisher, according to that, The development and approval of vaccines and nAbs against COVID-19 have happened incredibly quickly due to collaborative efforts among the global scientific community. The U.S. government has placed a pre-order for 100 million doses of Pfizer's BNT162b2 mRNA vaccine at a cost of $1.95 billion as early as July 22, 2020, and after one year, it has already placed orders for a total of 500 million doses.

Global Antibodies Market Segmentation:

The global antibodies market report is segmented into Drug Type, Disease Indication, End User, and Region

Based on Drug Type, the market is segmented into monoclonal antibodies, polyclonal antibodies, and antibody-drug complexes (ADCs). Out which the monoclonal antibodies segment is expected to hold a dominant position in the antibodies market over the forecast period.

Based Disease Indication, the antibodies market is segmented into CNS disorders, cardiovascular diseases, cancer, and autoimmune disorders.

Based on End User, the antibodies market is segmented into hospitals, long-term care facilities, and research institutes.

Antibodies Market Report Coverage

Report Coverage Details
Base Year: 2022 Market Size in 2023: US$ 224,083.5 Mn
Historical Data for: 2017 to 2021 Forecast Period: 2023 to 2030
Forecast Period 2023 to 2030 CAGR: 12.9% 2030 Value Projection: US$ 524,782.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC Countries, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Drug Type: Monoclonal antibodies, Polyclonal antibodies, Antibody-drug complexes (ADCs)
  • By Disease Indication: CNS Disorders, Cardiovascular Diseases, Cancer, Autoimmune Disorders         
  • By End User: Hospitals, Long-term Care Facilities, Research institutes
Companies covered:

Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd.

Growth Drivers:
  • Increasing number of product approval by the regulatory authorities
Restraints & Challenges:
  • High cost of the antibody therapy
  • Side effects associated with the antibody administration 

Global Antibodies Market Cross Sectional Analysis:

In drug type, the monoclonal antibodies segment is expected to hold a dominant position in the global antibodies market in North America over the forecast period. For instance, in October 2020, the U.S. Department of Health and Human Services (HHS), and Department of Defense (DOD), announced an agreement with AstraZeneca for late-stage development and large-scale manufacturing of the company’s COVID-19 investigational product AZD7442, a cocktail of two monoclonal antibodies, for the treatment against the SARS-CoV-2, the coronavirus that causes COVID-19.

Global Antibodies Market: Key Developments

For instance, in October 2020, IAVI, a nonprofit scientific research organization, and Serum Institute of India Pvt. Ltd., a manufacturer of vaccines and biologics, announced an agreement with Merck KGaA, a science and technology company, to develop SARS-CoV-2 neutralizing monoclonal antibodies (mAbs) co-invented by IAVI and Scripps Research as innovative interventions to address the COVID-19 pandemic.

Global Antibodies Market: Key Trends

Increasing authorizations for antibodies by the regulatory authorities

Increasing authorizations by the regulatory authorities is expected to drive the global antibodies market over the forecast period. For instance, in May 2021, Roche India, announced that the Central Drugs Standards Control Organization (CDSCO) has provided an Emergency Use Authorization (EUA) for Roche’s antibody cocktail (Casirivimab and Imdevimab) in India.

Global Antibodies Market: Restraint

Side effects associated with the antibodies

Use of antibodies may lead to some side effects such as serum sickness, acute anaphylaxis, and specific target-related adverse effects, which is also expected to hinder the market growth. To overcome the adverse effects of the drugs and antibodies, regulatory authorities should strictly monitor the products.

Global Antibodies Market - Key Players

Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Lilly., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc. and Kyowa Kirin Co., Ltd.

*Definition: An antibody, also called immunoglobulin, is a protein produced by plasma cells in response to specific antigens. These antibodies can be used as therapeutic as well as diagnostic purposes for several indications, including cancers, autoimmune disorders, inflammatory & infectious diseases, and others.

Frequently Asked Questions

The global antibodies market is estimated to be valued at US$ 2,24,083.5 million in 2023 and is expected to exhibit a CAGR of 12.9% between 2023 and 2030.

Increasing in the product approval by the regulatory authorities is expected to drive the market.

Monoclonal antibodies segment is the leading drug type segment in the market.

High cost of the antibody therapy is expected to hinder the growth of the market.

Novartis AG, F. Hoffmann-La Roche Ltd., Johnson & Johnson Services, Inc., Takeda Pharmaceutical Company Limited, Amgen Inc., Biogen Inc., Bristol-Myers Squibb Company, AbbVie Inc., Sanofi, Eli Lilly and Co., Iovance Biotherapeutics, Inc., Ultragenyx Pharmaceutical Inc., and Kyowa Kirin Co., Ltd.

View Our Licence Options

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports

Customize Now

Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail

Request Discount
Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients
trusted clients logo